1. Fatigue During and After Breast Cancer Therapy—A Prospective Study
Kristin V. Reinertsen, MD, PhD, Olav Engebraaten, MD, PhD, Jon H. Loge, Milada Cvancarova, MSc, PhD, Bjørn Naume, Erik Wist, Hege Edvardsen, MSc, PhD, Elisabeth Wille, MSc, Trine Bjøro, Cecilie E. Kiserud, MD, PhD 
Journal of Pain and Symptom Management 
Volume 53, Issue 3, Pages (March 2017)
DOI: /j.jpainsymman
Copyright © 2017 American Academy of Hospice and Palliative Medicine Terms and Conditions

2. Fig. 1
Cohort and treatment overview and assessments. BC = breast cancer.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 American Academy of Hospice and Palliative Medicine Terms and Conditions

3. Fig. 2
Course of total fatigue (TF) score, in the whole cohort and in women treated with and without bevacizumab. Median fatigue level on the y-axis and assessment points on the x-axis.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 American Academy of Hospice and Palliative Medicine Terms and Conditions

4. Fig. 3
Prevalence (%) of chronic fatigue (CF) in the whole cohort and in women treated with and without bevacizumab at T0, T1, T2, and T3. % CF on the y-axis and assessment points on the x-axis.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2017 American Academy of Hospice and Palliative Medicine Terms and Conditions